The American College of Rheumatology updated COVID-19 vaccine clinical guidance to include recommendations regarding medication timing considerations during the management of patients with rheumatic and musculoskeletal diseases.
Rheumatologists and rheumatology providers across the United States have expressed their support and provided guidance for patients in light of Rheumatoid Arthritis Awareness Day this year.
Experts at the ACR Convergence conference discussed the use of Janus kinase inhibitors before/after biologics following methotrexate treatment failure in RA.
A first look at the sessions and events scheduled at the American College of Rheumatology (ACR) Convergence 2020, to be held online from November 5 to 9, 2020.
Researchers investigated the risk for SARS-CoV-2 infection in patients with rheumatic disease receiving vs not receiving hydroxychloroquine.
![When communicating with patients, it is essential to provide them with key information about their drug regimen, including what the drug is, why they need it, when and how to take it, and for how long they need to take it. [6] They should also be educated about the fluctuating nature of RA, the consequences of nonadherence, and the potential adverse effects associated with their treatment so that they know what to expect and when to call for instruction, reducing the risk of them altering their regimen. [6,10] Because patients of lower socioeconomic status and ethnic minorities are at especially high risk of nonadherence, the RESPECT model of communicating, which has received recognition for improving cultural competence and overall rapport, might be especially beneficial in the RA setting. RESPECT comprises seven core elements: Respect (show), Explain (provide), Support (provide), Power (share), Empathy (show), Concerns (address), and Trust (build). [11]](https://1fxghyessyy2gaob23ygwzph-wpengine.netdna-ssl.com/wp-content/uploads/sites/18/2019/01/5doctorchartcomputerts541_1041336-544x306.jpg)
Study authors highlighted the challenges associated with the identification of published COVID-19 literature and suggested resources for rheumatologists and their patients.
There are significant differences in perceptions of prevalence, risk factors, and the management of RA-associated interstitial lung disease between rheumatologists and pulmonologists.
The American College of Rheumatology updated its COVID-19 guidance for the management of adult patients with rheumatic diseases.
Authors of this report assessed the role of iloprost in the management of COVID-19-related vasculopathy.
The American College of Rheumatology has issued a set of position statements for the use of telemedicine in the management of patients with rheumatic diseases.
